WHAT IS CLAIMED IS:

1. The use of a compound selected from the group consisting of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating cancer in a patient, wherein said cancer patient has at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3.

2. Use according to claim 1, wherein said at least one target gene is ROS1.

3. Use according to claim 1, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

4. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof.

5. Use according to claim 4, wherein said at least one target gene is ROS1.

6. Use according to claim 4, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

7. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof.

8. Use according to claim 7, wherein said at least one target gene is ROS1.

9. Use according to claim 7, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

10. Use according to claim 1, wherein said compound is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof.

11. Use according to claim 10, wherein said at least one target gene is ROS1.

12. Use according to claim 10, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

13. Use according to claim 1, wherein said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

14. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof, and said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

15. Use according to claim 14, wherein said cancer is selected from the group consisting of non-small cell lung cancer, neuroblastoma and colorectal cancer.

16. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof, and said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

17. Use according to claim 16, wherein said cancer is selected from the group consisting of non-small cell lung cancer, neuroblastoma and colorectal cancer.

18. Use according to claim 1, wherein said compound is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof, and said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

19. Use according to claim 18, wherein said cancer is selected from the group consisting of non-small cell lung cancer, neuroblastoma and colorectal cancer.

20. A compound selected from the group consisting of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof, for use in method of treating cancer in a patient having at least one

genetic alteration in at least one target gene selected from the group consisting of ROS1, NTRK1, NTRK2, and NTRK3, wherein said method comprises the steps of:

a) determining whether said patient has at least one genetic alteration in at least one target gene selected from the group consisting of ROS1, NTRK1, NTRK2, and NTRK3; and

b) administering a therapeutically effective amount of said compound to said cancer patient.

21. A compound for use according to claim 20, wherein said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

22. A method of treating cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, comprising administering to said cancer patient a therapeutically effective amount of a compound selected from N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof.

CLAIMS

1. The use of a compound selected from the group consisting of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating cancer, wherein said cancer has at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3.

2. Use according to claim 1, wherein said at least one target gene is ROS1.

3. Use according to claim 1, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

4. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof.

5. Use according to claim 4, wherein said at least one target gene is ROS1.

6. Use according to claim 4, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

7. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof.

8. Use according to claim 7, wherein said at least one target gene is ROS1.

9. Use according to claim 7, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

10. Use according to claim 1, wherein said compound is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof.

11. Use according to claim 10, wherein said at least one target gene is ROS1.

12. Use according to claim 10, wherein said at least one target gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.

13. Use according to claim 1, wherein said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

14. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof, and said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

15. Use according to claim 14, wherein said cancer is selected from the group consisting of non-small cell lung cancer, neuroblastoma and colorectal cancer.

16. Use according to claim 1, wherein said compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof, and said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

17. Use according to claim 16, wherein said cancer is selected from the group consisting of non-small cell lung cancer, neuroblastoma and colorectal cancer.

18. Use according to claim 1, wherein said compound is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof, and said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

19. Use according to claim 18, wherein said cancer is selected from the group consisting of non-small cell lung cancer, neuroblastoma and colorectal cancer.

20. A compound selected from the group consisting of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl) benzamide, or a pharmaceutically acceptable salt thereof, for use in treating cancer having at least one genetic alteration in at least one target gene selected from the group consisting of ROS1, NTRK1, NTRK2, and NTRK3.

21. A compound for use according to claim 20, wherein said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.